ROC Inc.

The ride COVID couldn’t stop – Ride 4 Research 2022 for Rare Ovarian Cancer Research

Ride 4 Research 2022 (R4R) riders have completed the last leg of the ride on Saturday 18 June 2022. 12 riders lead by R4R organiser Peter Reaburn set out from Canberra on 30 April to cycle 900km in 9 days, however the ride was cut short by two days as there was a COVID outbreak among the riders and support crew. Each of the riders completed the final distance in their own State joined by family and friends A huge congratulation and heartfelt thank you to all the riders, support crew, supporters, major sponsors and to all of you who […]

11-month-old baby Neve’s ovarian tumour was bigger than a softball.

11-month-old baby Neve’s ovarian tumour was bigger than a softball. Imagine being diagnosed with ovarian cancer as a baby. Unfortunately, this was the confronting reality Neve and her parents Jo and Zoe found themselves in on August 1, 2014. Aged just 11 months old, Neve was diagnosed with Juvenile Granulosa Cell Tumour (jGCT) – a recurrent, incurable ovarian cancer that has no effective treatments available post-surgery. Most people associate ovarian cancer as a disease affecting adult women. Few people know that ovarian cancer can be diagnosed at any age and affects females of all ages. So little is known about […]

11-month-old baby Neve’s ovarian tumour was bigger than a softball.

11-month-old baby Neve’s ovarian tumour was bigger than a softball. Imagine being diagnosed with ovarian cancer as a baby. Unfortunately, this was the confronting reality Neve and her parents Jo and Zoe found themselves in on August 1, 2014. Aged just 11 months old, Neve was diagnosed with Juvenile Granulosa Cell Tumour (jGCT) – a recurrent, incurable ovarian cancer that has no effective treatments available post-surgery. Most people associate ovarian cancer as a disease affecting adult women. Few people know that ovarian cancer can be diagnosed at any age and affects females of all ages. So little is known about […]

Consumers working with researchers for a rare ovarian cancer.

It has been an exciting start to the second half of the year for a rare ovarian cancer called Granulosa Cell Tumour (GCT). Previously GCT has received very little research to be able to have standard protocols for treatment. Consumers from around the world are helping researchers at the Hudson Institute of Medical Research in Melbourne Australia to gain more insight into this rare disease with collected data information from the GCT Survivor Sisters and tumour tissue samples from patients. Kim Eroh the founder of the Facebook group GCT Survivor Sisters in 2012 created the group to be able to […]